Mannkind (MNKD) Long-Term Investments (2021 - 2025)
Mannkind (MNKD) posted quarterly Long-Term Investments of $5.0 million for Q4 2025, down 8.57% year-over-year from $5.5 million in Q4 2024, and down 80.89% quarter-over-quarter from $26.2 million in Q3 2025.
Mannkind (MNKD) Long-Term Investments (2021 - 2025) Analysis & Trends
Mannkind (MNKD) has reported Long-Term Investments for 5 consecutive years, with $5.0 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Long-Term Investments fell 8.57% year-over-year to $5.0 million; the TTM figure through Dec 2025 stood at $5.0 million (down 8.57% YoY), while the FY2025 annual figure was $5.0 million, down 8.57% from the prior year.
- Long-Term Investments declined to $5.0 million in Q4 2025 per MNKD's latest filing, from $26.2 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $70.5 million in Q1 2022 and bottomed at $492000.0 in Q1 2023.
- Historically, Long-Term Investments has averaged $19.0 million across 5 years, with a median of $13.0 million in 2022.
- Annual changes were most pronounced in 2022 — Long-Term Investments surged 4602.8% — and 2023, when it sank 99.3%.
- Mannkind's Long-Term Investments stood at $56.6 million in 2021, then sank by 96.54% to $2.0 million in 2022, then soared by 264.86% to $7.2 million in 2023, then retreated by 23.38% to $5.5 million in 2024, then declined by 8.57% to $5.0 million in 2025.
- Business Quant data shows MNKD's Long-Term Investments at $5.0 million in Q4 2025, $26.2 million in Q3 2025, and $22.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Mannkind | 1.19 Bn | 1.08 Bn | 94.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.01 Mn |
| Sep 30, 2025 | 26.23 Mn |
| Jun 30, 2025 | 22.24 Mn |
| Mar 31, 2025 | 16.68 Mn |
| Dec 31, 2024 | 5.48 Mn |
| Sep 30, 2024 | 16.80 Mn |
| Jun 30, 2024 | 13.40 Mn |
| Mar 31, 2024 | 3.73 Mn |
| Dec 31, 2023 | 7.16 Mn |
| Sep 30, 2023 | 3.27 Mn |
| Jun 30, 2023 | 2.28 Mn |
| Mar 31, 2023 | 492,000.00 |
| Dec 31, 2022 | 1.96 Mn |
| Sep 30, 2022 | 12.70 Mn |
| Jun 30, 2022 | 32.60 Mn |
| Mar 31, 2022 | 70.54 Mn |
| Dec 31, 2021 | 56.62 Mn |
| Sep 30, 2021 | 42.10 Mn |
| Jun 30, 2021 | 39.00 Mn |
| Mar 31, 2021 | 1.50 Mn |